Implementation of a Pharmacy-Intervention to Enhance Prescription and Use of Lipid-Lowering Drugs
1 other identifier
interventional
70
1 country
1
Brief Summary
The purpose of this study is to determine the effectiveness of maximal support of community pharmacies to implement a pharmaceutical care model for improving underprescription and treatment persistence regarding lipid-lowering medication in patients with cardiovascular disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable cardiovascular-diseases
Started Oct 2006
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2006
CompletedFirst Submitted
Initial submission to the registry
February 28, 2007
CompletedFirst Posted
Study publicly available on registry
July 31, 2007
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 2008
CompletedJuly 10, 2008
July 1, 2008
1.3 years
February 28, 2007
July 9, 2008
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
The percentage of selected (=undertreated) patients receiving at least one prescription for lipid-lowering medication.
six months after the general practitioner received the list with selected patients
Secondary Outcomes (1)
Differences in prescribing for age categories and co-medication.
six months
Study Arms (2)
experimental
EXPERIMENTALcontrol
ACTIVE COMPARATORInterventions
educational manual; interactive educational meeting tailored to individual needs; reminders and feedback by 3 newsletters and at least 3 telephone calls.
Eligibility Criteria
You may qualify if:
- pharmacies: resident in the south of the Netherlands
- patients: with antiplatelet therapy and without lipid-lowering medication
You may not qualify if:
- terminal disease
- severe mental disorder
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Radboud University Medical Centerlead
- Zorgverzekeraar CZcollaborator
- Scientific Institute for Dutch Pharmacists, The Netherlandscollaborator
Study Sites (1)
UMC St Radboud, Scientific Institute for Quality of Healthcare
Nijmegen, NL, 6500 HB, Netherlands
Related Publications (10)
Mantel-Teeuwisse AK, Verschuren WM, Klungel OH, de Boer A, Kromhout D. Recent trends in (under)treatment of hypercholesterolaemia in the Netherlands. Br J Clin Pharmacol. 2004 Sep;58(3):310-6. doi: 10.1111/j.1365-2125.2004.02152.x.
PMID: 15327591BACKGROUNDBlenkinsopp A, Anderson C, Armstrong M. Systematic review of the effectiveness of community pharmacy-based interventions to reduce risk behaviours and risk factors for coronary heart disease. J Public Health Med. 2003 Jun;25(2):144-53. doi: 10.1093/pubmed/fdg030.
PMID: 12848404BACKGROUNDGrimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, Whitty P, Eccles MP, Matowe L, Shirran L, Wensing M, Dijkstra R, Donaldson C. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess. 2004 Feb;8(6):iii-iv, 1-72. doi: 10.3310/hta8060.
PMID: 14960256BACKGROUNDHeart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002 Jul 6;360(9326):7-22. doi: 10.1016/S0140-6736(02)09327-3.
PMID: 12114036BACKGROUNDGaw A. The care gap: underuse of statin therapy in the elderly. Int J Clin Pract. 2004 Aug;58(8):777-85. doi: 10.1111/j.1368-5031.2004.00300.x.
PMID: 15372851BACKGROUNDTeeling M, Bennett K, Feely J. The influence of guidelines on the use of statins: analysis of prescribing trends 1998-2002. Br J Clin Pharmacol. 2005 Feb;59(2):227-32. doi: 10.1111/j.1365-2125.2004.02256.x.
PMID: 15676046BACKGROUNDvan Wyk JT, Picelli G, Dieleman JP, Mozaffari E, Kramarz P, van Wijk MA, van der Lei J, Sturkenboom MC. Management of hypertension and hypercholesterolaemia in primary care in The Netherlands. Curr Med Res Opin. 2005 Jun;21(6):839-48. doi: 10.1185/030079905X46368.
PMID: 15969884BACKGROUNDNederlands Huisartsen Genootschap (NHG). NHG-standaard Cardiovasculair Risicomanagement. 2006 Jan.
BACKGROUNDStuurman-Bieze AG, de Boer WO, Kokenberg ME, Hugtenburg JG, de Jong-van den Berg LT, Tromp TF. Complex pharmaceutical care intervention in pulmonary care: part A. The process and pharmacists' professional satisfaction. Pharm World Sci. 2005 Oct;27(5):376-84. doi: 10.1007/s11096-005-7112-9.
PMID: 16341744BACKGROUNDVan de Steeg-van Gompel CH, Wensing M, De Smet PA. Implementation of patient education at first and second dispensing of statins in Dutch community pharmacies: the sequel of a cluster randomized trial. BMC Health Serv Res. 2011 Nov 16;11:313. doi: 10.1186/1472-6963-11-313.
PMID: 22087850DERIVED
MeSH Terms
Conditions
Study Officials
- PRINCIPAL INVESTIGATOR
Peter G. de Smet, PhD
Radboud University Medical Center
- STUDY DIRECTOR
Michel Wensing, PhD
Scientific Institute for Quality of Healthcare
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- HEALTH SERVICES RESEARCH
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
February 28, 2007
First Posted
July 31, 2007
Study Start
October 1, 2006
Primary Completion
February 1, 2008
Study Completion
March 1, 2008
Last Updated
July 10, 2008
Record last verified: 2008-07